Jiangsu Hengrui Medicine
600276.SS
#424
Rank
NZ$94.61 B
Marketcap
NZ$14.26
Share price
1.92%
Change (1 day)
30.83%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): NZ$1.99 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are NZ$4.19 Billion. In 2024 the company made an earning of NZ$1.64 Billion, an increase over its 2023 earnings that were of NZ$1.09 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.99 B21.29%
2024 NZ$1.64 B50.59%
2023 NZ$1.09 B11.35%
2022 NZ$0.98 B-13.82%
2021 NZ$1.13 B-34.16%
2020 NZ$1.72 B16.28%
2019 NZ$1.48 B32.92%
2018 NZ$1.11 B20.82%
2017 NZ$0.92 B23.8%
2016 NZ$0.74 B11.25%
2015 NZ$0.67 B39.52%
2014 NZ$0.48 B20.71%
2013 NZ$0.39 B11.46%
2012 NZ$0.35 B29.6%
2011 NZ$0.27 B31.28%
2010 NZ$0.21 B27.89%
2009 NZ$0.16 B5.84%
2008 NZ$0.15 B79.89%
2007 NZ$86.45 M32.93%
2006 NZ$65.03 M38.14%
2005 NZ$47.07 M21.56%
2004 NZ$38.72 M13.95%
2003 NZ$33.98 M38.06%
2002 NZ$24.61 M